目的 研究桂芍鎮(zhèn)癇片聯(lián)合丙戊酸鈉緩釋片治療小兒癲癇的臨床療效。方法 選取2017年12月-2019年12月許昌市第二人民醫(yī)院收治的92例癲癇患兒為研究對(duì)象，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各46例。對(duì)照組患兒口服丙戊酸鈉緩釋片，30 mg/（kg·d），3次/d。治療組在對(duì)照組基礎(chǔ)上口服桂芍鎮(zhèn)癇片，6片/次，3次/d。兩組患兒持續(xù)治療2個(gè)月。觀察兩組的臨床療效，比較兩組的臨床癥狀情況、血清炎性因子腫瘤壞死因子-α（TNF-α）、高敏C反應(yīng)蛋白（hs-CRP）和白細(xì)胞介素-6（IL-6）水平以及血清學(xué)指標(biāo)。結(jié)果 治療后，治療組總有效率95.65%，顯著高于對(duì)照組的80.43%（P<0.05）。治療后，兩組患兒癲癇發(fā)作次數(shù)和平均癥狀控制時(shí)間明顯降低（P<0.05）；且治療組降低的較多（P<0.05）。治療后，兩組血清TNF-α、hs-CRP和IL-6水平顯著降低（P<0.05）；并且治療組血清炎性因子水平顯著低于對(duì)照組（P<0.05）。治療后，兩組血清腦源性神經(jīng)營(yíng)養(yǎng)因子（BDNF）和神經(jīng)元特異性烯醇化酶（NSE）水平顯著降低（P<0.05）；并且治療組血清BDNF和NSE水平顯著低于對(duì)照組（P<0.05）。結(jié)論 桂芍鎮(zhèn)癇片聯(lián)合丙戊酸鈉緩釋片治療小兒癲癇具有較好的臨床療效，能夠改善臨床癥狀，降低血清因子水平，值得在臨床上推廣應(yīng)用。

Objective To study the effect of Guishao Zhenxian Tablets combined with Sodium Valproate Sustained-release Tablets in treatment of epilepsy in children. Methods Children (84 cases) with epilepsy in the Second People's Hospital of Xuchang from December 2017 to December 2019 were randomly divided into control and treatment groups, and each group had 46 cases. Children in the control group were po administered with Sodium Valproate Sustained-release Tablets, 30 mg/(kg·d), three times daily. Children in the treatment group were po administered with Guishao Zhenxian Tablets on the basis of the control group, 6 tablets/time, three times daily. Patients in two groups were treated for 2 months. After treatment, the clinical efficacies were evaluated, and clinical symptom; serological indexes, the serum levels of inflammatory factors TNF-α, hs-CRP, and IL-6 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.65%, which was significantly higher than that of the control group (80.43%) (P<0.05). After treatment, the seizure frequency and the average symptom control time of two groups were significantly reduced (P<0.05), and these indexes in the treatment group were much lower than those in the control group (P<0.05). After treatment, the serum levels of TNF-α, hs-CRP and IL-6 in two groups were significantly decreased (P<0.05); and the serum levels of inflammatory factors in the treatment group were significantly lower than those in the control group (P<0.05). After treatment, the serum levels of BDNF and NSE in the two groups were significantly decreased (P<0.05), and the serum levels of BDNF and NSE in the treatment group were significantly lower than those in the control group (P<0.05). Conclusion Guishao Zhenxian Tablets combined with Sodium Valproate Sustained-release Tablets has clinical curative effect in treatment of epilepsy in children, can improve clinical symptoms and reduce serum factor level, which is worthy of clinical application.

R985

河南省科技攻關(guān)項(xiàng)目（2018ZY2095）